Published in Biotech Business Week, December 27th, 2004
The results showed a favorable safety profile, excellent pharmacokinetics and tolerable taste. The successful completion of the study moves APT forward to financing efforts and efficacy studies.
Hydroxychloroquine is best known as a treatment for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.